Highlights

  • Racura Oncology Limited (ASX: RAC) lodged an Appendix 3H dated 13 July 2026 recording that 270,000 options ceased on 12 July 2026.
  • The options, under code RACAL and described as "OPTION EXPIRING 12-JUL-2026 EX $4.76", expired without being exercised or converted.
  • The exercise price on the lapsed options was $4.76, and no consideration was paid by the company for the cessation.
  • Because the options were never exercised, no new shares were issued; issued capital stands at 196,068,940 ordinary fully paid shares.
  • The expiry is a routine administrative and capital-structure event that generated no cash and did not materially change the ordinary share count.

Racura Oncology Limited (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company built around a single mission that it summarises as an ambition to "silence cancer". While the market's attention naturally gravitates to the company's clinical pipeline, listed entities are also required to keep shareholders informed about the more procedural side of corporate life, including any changes to their capital structure. One such change was recorded in mid-July 2026, when Racura Oncology lodged a short notice confirming that a parcel of options had reached the end of its life. On its own the notice is unremarkable, but it offers a useful opportunity to explain how options and exercise prices work. This article examines that filing and sticks strictly to what the announcement says about ASX: RAC and nothing more.

Inside the Announcement

The document is an Appendix 3H, the standard ASX form a company uses to notify the market that certain securities have ceased to exist. Racura Oncology's Appendix 3H is dated 13 July 2026 and records the cessation of 270,000 options carrying the code RACAL and the descriptor "OPTION EXPIRING 12-JUL-2026 EX $4.76". The stated reason is expiry without exercise or conversion, and the date of cessation is 12 July 2026.

Two further details matter for understanding the event correctly. First, the exercise price attaching to these options was $4.76. Second, no consideration was paid by the entity in connection with the cessation. In other words, the company did not buy the options back or pay anything to retire them; they simply lapsed at their contractual expiry date.

The filing also updates Racura Oncology's issued-capital position. Following the change, the RACAL line shows a balance of zero, and the company reports 196,068,940 ordinary fully paid shares on issue under the code RAC : ORDINARY FULLY PAID. This ordinary share figure is the number to keep in mind, because it demonstrates what did and did not happen when the options expired. The Appendix 3H is, at heart, a housekeeping notice rather than a statement about the business itself.

Background: Racura Oncology and RC220

To place the notice in context, it helps to recall what Racura Oncology does. The company is developing (E,E)-bisantrene, a small-molecule anticancer agent that primarily acts through G-quadruplex (G4) DNA and RNA binding, an interaction that leads to silencing of MYC (c-MYC), an important regulator of cancer growth. According to the company, (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile. Recent discoveries have also enabled composition-of-matter intellectual property filings that the company says may provide up to 20 years of patent protection, though that protection is not guaranteed.

RC220 is a proprietary formulation of (E,E)-bisantrene developed by Racura, and it sits at the centre of three clinical programs: a Phase 3 program in acute myeloid leukaemia (AML) targeting c-MYC silencing; HARNESS-1, a Phase 1 trial combining RC220 with Tagrisso (osimertinib) in mutant EGFR non-small cell lung cancer; and CPACS, a Phase 1 program combining RC220 with doxorubicin in solid tumours. None of this pipeline activity is affected by the options expiry, but it explains why a small change in the option register is administrative rather than operational in nature.

Understanding Options, Exercise Prices and Unexercised Expiry

The core of this update is a concept that every equity investor eventually meets: the option and its exercise price. Understanding the mechanics makes it clear why an expiry like this one is a non-event for the underlying business.

What an exercise price actually is

An option issued by a company is a contract that gives its holder the right, but not the obligation, to buy a set number of new shares at a fixed price within a defined window of time. That fixed price is called the exercise price, or sometimes the strike price. In Racura Oncology's case, the RACAL options carried an exercise price of $4.76, which means each option entitled its holder to pay $4.76 to the company in exchange for one new ordinary share, provided they did so before the expiry date of 12 July 2026.

The exercise price is set when the options are first issued and does not change over the life of the instrument. It effectively defines the cost of converting an option into a share. Because that cost is fixed while a company's share price can move over time, the value of an option to its holder depends on the relationship between the two.

Why holders may choose not to exercise

An option holder is never compelled to act. When options approach expiry, the holder weighs the exercise price against the benefit of acquiring shares at that price. As a general principle that applies across the market, holders tend not to exercise options when the exercise price is at or above the prevailing share price, because they could simply buy shares on-market for the same or a lower outlay rather than paying the fixed exercise price to the company. In that situation an option is often described as being "out of the money", and allowing it to lapse costs the holder nothing beyond whatever they originally paid for the option.

It is important to be precise here. The Appendix 3H does not disclose Racura Oncology's share price, and this article makes no assertion about where RAC shares trade relative to $4.76. What the filing tells us is simply that none of the 270,000 options were exercised before expiry. The general concept above explains why unexercised expiries occur, but it is not evidence about RAC's valuation, and readers should not infer one.

What "ceased" means on the register

When options expire unexercised, they are extinguished. They convert into nothing: no shares, no cash, no residual entitlement. That is why the Appendix 3H shows the RACAL balance falling to zero. The alternative outcome, exercise, would have seen holders pay $4.76 per option to receive newly issued shares, which would have both raised cash for the company and increased the ordinary share count. Neither of those things happened here, which is exactly why the ordinary share total remains at 196,068,940.

What It Could Mean for ASX: RAC

For Racura Oncology, the practical consequences of this event are minimal and purely administrative. No cash flowed into the company, because exercise, not expiry, is what would have delivered funds. The ordinary share count did not materially change, because no new shares were created. In dilution terms, the expiry marginally reduces the pool of securities that could ever convert into ordinary shares, but the effect on the overall capital structure is modest and does not alter the number of shares already on issue.

This parcel of options was not the company's only unquoted option class. Racura Oncology retains a number of other unquoted option classes on issue across various codes, prices and expiry dates. The cessation of the RACAL line therefore represents the retirement of one specific tranche rather than a wholesale change to the company's option arrangements. Investors reviewing the fully diluted position should keep those remaining classes in view.

Limitations and Key Risks

The single most important limitation to state plainly is that this options expiry is immaterial to Racura Oncology's operations. It is a capital-structure notification, not a clinical or commercial milestone, and it should not be read as evidence of business progress or deterioration in either direction. Nothing in an Appendix 3H speaks to trial results, regulatory standing or the company's financial runway.

The substantive risks facing Racura Oncology remain those inherent to clinical-stage biotechnology. Clinical risk is significant: RC220 is being evaluated across Phase 1 and Phase 3 programs, and early or acceptable safety signals do not establish efficacy, nor do preclinical findings constitute clinical proof. Regulatory risk is ever-present, as advancing any candidate toward approval depends on satisfying demanding authorities. Funding risk matters because drug development is capital intensive, and this event generated no cash to help meet those needs. Execution risk spans the practical challenges of running multi-country trials. Commercialisation risk remains, since the company is only exploring partnerships, licence agreements and merger and acquisition opportunities, with nothing signed. None of these risks is changed by the options expiry, but all remain relevant.

What Investors May Watch Next

Given the administrative nature of this notice, the more meaningful signals for Racura Oncology will come from elsewhere. Investors may monitor future capital-structure disclosures, including any Appendix 3B or Appendix 2A filings that would follow if other options are exercised and new shares are issued, or further Appendix 3H notices as additional option tranches reach their expiry dates. Because the company retains multiple unquoted option classes, the register will continue to evolve over time.

Beyond the register, the company's clinical calendar is where the substantive developments lie, across its AML, HARNESS-1 and CPACS programs. Those updates, rather than routine option expiries, are what will shape the fundamental story. The ordinary share count of 196,068,940 provides a baseline against which any future changes to issued capital can be measured.

Conclusion

The expiry of 270,000 RACAL options at a $4.76 exercise price is precisely the kind of event that rewards careful reading. Racura Oncology (ASX: RAC) recorded the cessation in an Appendix 3H dated 13 July 2026, confirming that the options lapsed unexercised on 12 July 2026, that no consideration was paid, and that issued capital stands at 196,068,940 ordinary fully paid shares. Understanding the mechanics, that an exercise price is the fixed cost of converting an option into a share, and that unexercised options simply extinguish, makes clear why this is a housekeeping matter that generated no cash and left the ordinary share count essentially unchanged. It is neither good news nor bad news about the underlying business; it is simply the tidy closure of one line on Racura Oncology's securities register.